543 related articles for article (PubMed ID: 28728756)
21. Soluble Urokinase Receptor and Chronic Kidney Disease.
Hayek SS; Sever S; Ko YA; Trachtman H; Awad M; Wadhwani S; Altintas MM; Wei C; Hotton AL; French AL; Sperling LS; Lerakis S; Quyyumi AA; Reiser J
N Engl J Med; 2015 Nov; 373(20):1916-25. PubMed ID: 26539835
[TBL] [Abstract][Full Text] [Related]
22. SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis.
Hodges GW; Bang CN; Eugen-Olsen J; Olsen MH; Boman K; Ray S; Gohlke-Bärwolf C; Kesäniemi YA; Jeppesen JL; Wachtell K
Can J Cardiol; 2016 Dec; 32(12):1462-1469. PubMed ID: 27499378
[TBL] [Abstract][Full Text] [Related]
23. Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients.
Huang Y; Zhou H; Wu Y; Yang Y; Li W; Lu J; Hu Y
Dis Markers; 2017; 2017():4719403. PubMed ID: 29109596
[TBL] [Abstract][Full Text] [Related]
24. The Plasma Soluble Urokinase Plasminogen Activator Receptor Is Related to Disease Activity of Patients with ANCA-Associated Vasculitis.
Huang F; Li Y; Xu R; Cheng A; Lv Y; Liu Q
Mediators Inflamm; 2020; 2020():7850179. PubMed ID: 32322165
[TBL] [Abstract][Full Text] [Related]
25. Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation.
Proietti M; Raparelli V; Laroche C; Dan GA; Janion M; Popescu R; Sinagra G; Vijgen J; Boriani G; Maggioni AP; Tavazzi L; Lip GYH;
Europace; 2017 Sep; 19(9):1439-1448. PubMed ID: 27940934
[TBL] [Abstract][Full Text] [Related]
26. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
[TBL] [Abstract][Full Text] [Related]
28. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
[No Abstract] [Full Text] [Related]
29. The role of novel cytokines in inflammation: Defining peripheral artery disease among patients with coronary artery disease.
Ozkaramanli Gur D; Guzel S; Akyuz A; Alpsoy S; Guler N
Vasc Med; 2018 Oct; 23(5):428-436. PubMed ID: 29638194
[TBL] [Abstract][Full Text] [Related]
30. Left ventricular ejection fraction is associated with prevalent and incident cardiovascular disease in patients with intermittent claudication - results from the CAVASIC Study.
Rantner B; Pohlhammer J; Stadler M; Peric S; Hammerer-Lercher A; Klein-Weigel P; Fraedrich G; Kronenberg F; Kollerits B
Atherosclerosis; 2015 Apr; 239(2):428-35. PubMed ID: 25682043
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease.
Lee JY; Lee SW; Lee WS; Han S; Park YK; Kwon CH; Jang JY; Cho YR; Park GM; Ahn JM; Kim WJ; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
JACC Cardiovasc Interv; 2013 Dec; 6(12):1303-13. PubMed ID: 24355120
[TBL] [Abstract][Full Text] [Related]
32. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease.
Lv L; Wang F; Wu L; Wang JW; Cui Z; Hayek SS; Wei C; Reiser J; He K; Zhang L; Chen M; Zhao MH
Nephrol Dial Transplant; 2020 Mar; 35(3):465-470. PubMed ID: 30124995
[TBL] [Abstract][Full Text] [Related]
33. Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
Ishikawa H; Izumiya Y; Shibata A; Ichikawa Y; Yamaguchi T; Yamaguchi Y; Kitada R; Iwata S; Ehara S; Tomita S; Hanatani A; Yoshiyama M
Heart Vessels; 2020 May; 35(5):681-688. PubMed ID: 31741050
[TBL] [Abstract][Full Text] [Related]
34. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction.
Subherwal S; Bhatt DL; Li S; Wang TY; Thomas L; Alexander KP; Patel MR; Ohman EM; Gibler WB; Peterson ED; Roe MT
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):541-9. PubMed ID: 22715460
[TBL] [Abstract][Full Text] [Related]
35. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
Borné Y; Persson M; Melander O; Smith JG; Engström G
Eur J Heart Fail; 2014 Apr; 16(4):377-83. PubMed ID: 24464777
[TBL] [Abstract][Full Text] [Related]
36. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
[TBL] [Abstract][Full Text] [Related]
37. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
[TBL] [Abstract][Full Text] [Related]
38. YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients.
Höbaus C; Tscharre M; Herz CT; Pesau G; Wrba T; Koppensteiner R; Schernthaner GH
Atherosclerosis; 2018 Jul; 274():152-156. PubMed ID: 29783062
[TBL] [Abstract][Full Text] [Related]
39. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
40. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
